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Effects of the lysosomal destabilizing drug
siramesine on glioblastoma in vitro and
in vivo
Stine S. Jensen1,2, Stine A. Petterson1,2, Bo Halle1,2,3, Charlotte Aaberg-Jessen1,2 and Bjarne W. Kristensen1,2*
Abstract
Background: Glioblastoma is the most frequent and most malignant brain tumor with the patients having a
median survival of only 14.6 months. Although glioblastoma patients are treated with surgery, radiation and
chemotherapy recurrence is inevitable. A stem-like population of radio- and chemoresistant brain tumor-initiating
cells combined with the invasive properties of the tumors is believed to be critical for treatment resistance. In the
present study, the aim was to investigate the effect of a novel therapeutic strategy using the lysosomotropic
detergent siramesine on glioblastomas.
Methods: Standard glioma cell lines and patient-derived spheroids cultures with tumor-initiating stem-like cells
were used to investigate effects of siramesine on proliferation and cell death. Responsible mechanisms were
investigated by inhibitors of caspases and cathepsins. Effects of siramesine on migrating tumor cells were investigated
by a flat surface migration assay and by implanting spheroids into organotypic rat brain slice cultures followed by
confocal time-lapse imaging. Finally the effect of siramesine was investigated in an orthotopic mouse glioblastoma
model. Results obtained in vitro and in vivo were confirmed by immunohistochemical staining of histological sections
of spheroids, spheroids in brain slice cultures and tumors in mice brains.
Results: The results showed that siramesine killed standard glioma cell lines in vitro, and loss of acridine orange
staining suggested a compromised lysosomal membrane. Co-treatment of the cell lines with inhibitors of
caspases and cathepsins suggested differential involvement in cell death. Siramesine caused tumor cell death and
reduced secondary spheroid formation of patient-derived spheroid cultures. In the flat surface migration model
siramesine caused tumor cell death and inhibited tumor cell migration. This could not be reproduced in the
organotypic three dimensional spheroid-brain slice culture model or in the mice xenograft model.
Conclusions: In conclusion the in vitro results obtained with tumor cells and spheroids suggest a potential of
lysosomal destabilizing drugs in killing glioblastoma cells, but siramesine was without effect in the organotypic
spheroid-brain slice culture model and the in vivo xenograft model.
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Background
The standard treatment of glioblastomas includes surgi-
cal resection, fractionated radiation and concomitant as
well as adjuvant chemotherapy with temozolomide. This
treatment has improved survival but despite these
improvements the median survival is only 14.6 months
[1]. Two biological aspects believed to be highly respon-
sible for tumor recurrence are the resistant tumor stem-
like cells [2] and the invasive properties of glioblastomas
[3]. Treatments targeting the tumor stem cells and the
invasive cells are therefore of great interest.
The lysosomal cell death pathway involves lysosomal
membrane permeabilization, thus being a cell death path-
way still functional in the tumor cells. By lysosomal mem-
brane permeabilization the lysosomal content translocates
to the cytosol and may cause programmed cell death [4,
5]. Among the proteases responsible for this cell death are
the cathepsins, which are still active at neutral pH [4].
Most excitingly the cathepsins are capable of inducing a
caspase-independent and mitochondrial-independent cell
death promoting cell death in tumor cells with multiple
defects in the classical apoptosis pathway [6].
A compound shown to accumulate in the lysosomes
causing lysosomal membrane permeabilization and release
of the cathepsins to the cytosol is the σ 2 receptor agonist,
siramesine (Lu-28-179; 1 V-[4-[1-(4-fluorphenyl)-1H-indol-
3-yl] butan-1-yl]spiro[isobenzofuran-1(3H),4 V-piperidine]).
Siramesine was originally designed to treat anxiety and
depression and it was shown to successfully enter the
brain in mice ex-vivo binding studies [7]. The drug was
well tolerated and non-toxic in humans but the effect
was not satisfactory [8]. Because of the lack of side ef-
fects and the suggested role of σ 2 receptors triggering
cell death, siramesine was investigated as an anti-
cancer drug [9]. Indeed, siramesine induced cell death
in immortalized and tumorigenic cells [9] by lysosomal
leakage of cathepsins and oxidative stress [10]. Sirame-
sine was found to directly destabilize the lysosomal
membrane followed by lysosomal dysfunction leading
to permeabilization of the membrane and release of ca-
thepsins to the cytosol resulting in cathepsin mediated
cell death [9, 10]. Importantly, the cell death was inde-
pendent of caspases and P53 tumor suppressor protein
and insensitive to the anti-apoptotic effect of Bcl-2 [9–11].
The aim of the current study was to investigate the
effect of siramesine on glioblastoma cells using ap-
proaches comprising both immature tumor stem-like
cells, differentiated tumor cells and migrating tumor
cells. Accordingly, we used both standard glioma cell
lines and patient-derived spheroids cultures with
tumor-initiating stem-like cells [12, 13]. To perform a
thorough testing, spheroid cultures were implanted in
three dimensionel organotypic brain slice cultures [13,
14] and used for generation of patient-like tumors in a
glioblastoma xenograft mice model [12, 15, 16]. Using
these approaches the in vitro results with tumor cells
and spheroids suggested a potential of lysosomal desta-
bilizing drugs in killing glioblastoma cells, but in the
organotypic spheroid-brain slice culture model and the
in vivo xenograft model siramesine was without effect.
Methods
Cells and treatments
In the present study we used the commercial human
glioma cell lines, U87, A172, T98G (all from European
Collection of Cell Cultures (ECACC), catalogue num-
bers: 89081402, 88062428 and 92090213, respectively)
and U251 (from CLS, cell lines service, Germany, cata-
logue number: 300385) cultured in serum containing
medium as described earlier [12].
The glioblastoma stem cell-like containing spheroid
(GSS) cultures T78, T86 and T87 were established in
our laboratory and cultured under stem cell promoting
conditions as neurospheres (spheroids). The spheroids
were cultured in serum-free medium as described earlier
[12]. The GSS cultures have the ability to form new
spheroids at clonal density, a karyotype typical of glio-
blastomas, the ability to differentiate into cells express-
ing neuronal, astrocytic and oligodendrocyte markers
upon culturering in serum-containing medium and the
ability to form highly invasive tumors upon orthotopic
xenografting [15].
Siramesine was kindly provided by H. Lundbeck A/S,
Valby, Denmark. Dimethylsulfoxid (DMSO) was used as
a solvent for siramesine in all in vitro studies. The
cathepsin and caspase inhibitors used were z-FA-FMK
(cathepsin B, L and S), Ca-074-Me (irreversible
capthepsin B inhibitor), z-DEVD-FMK (caspase 3 and
7), and z-DEVD-CMK (caspase 3), all from Bachem.
The inhibitors were added 1 h before the addition of
siramesine. The glioma cell lines were incubated with
inhibitors and siramesine for 48 h before measuring cell
proliferation and viability.
Cell proliferation and viability in adherent glioma
cell lines
The cell proliferation was analysed using the cell prolif-
eration reagent WST-1 (2-(4-Iodophenyl)-3-(4-nitrophe-
nyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium
salt, from Roche) according to the manufactures instruc-
tions. After 24 or 48 h of incubation of cells with sirame-
sine, the WST-1 reagent was added and the absorbance
at 450 nm was found using an absorbance microplate
reader (BioTek ELx808, Holm and Halby, Denmark).
A lactate dehydrogenase kit (LDH Cytotoxicity Detec-
tion Kit, Roche) was used to detect cell death according to
the manufactures instructions, detecting LDH released
from cells with a permeabilized membrane. Medium from
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each well in a 96-well plate was transferred to a new plate
where after the LDH reaction mix were added and the ab-
sorbance measured at 450 nm in the absorbance micro-
plate reader.
Change in lysosomal acidity
The glioma cell lines were incubated in 12 well glass
bottom plates until approximately 80% confluence and
exposed to siramesine (5–30 μM). After 1 h, Acridine
orange (5 μg/ml, Invitrogen) was added to the cells and
incubated for 15 min at 37 °C. Images were recorded
using confocal microscopy (Nikon, Inverted Microscope,
ECLIPSE TE2000-E). Analysis was made using the image
analysis tool Visiomorph™ (Visiopharm, Hørsholm,
Denmark). The results represent the proportion of red/
green + yellow area, accounting for the loss of red stain-
ing and gain of green and yellow staining in the cells.
Cell death in GSS spheroid cultures
Cell death in the GSS spheroid cultures was analyzed
using propidium iodide (PI) (2 μM, Invitrogen) and
Hoechst 33342 (10 mM, Invitrogen). The spheroids were
treated with siramesine for 24 h before addition of PI for
1 h followed by Hoechst for 15 min. The spheroids were
then analyzed using a confocal microscope recording z-
stacks which afterwards were superimposed into one
image. The images were analyzed using the image ana-
lysis tool Visiomorph establishing a classifier identifying
the PI uptake as red staining area and the total nuclear
area as the sum of red staining and blue Hoechst stain-
ing. The area ratio between red staining and red plus
blue staining was calculated.
Secondary spheroids formation after siramesine
treatment
Spheroids treated with siramesine for 24 h were dissoci-
ated, the cells were counted and 1000 cell/ml were added
to each well in a six-well plate. The cells were allowed to
form secondary spheroids and after 2–3 weeks the num-
ber of spheroids in each well was counted.
Immunohistochemical staining of GSS cultures exposed
to siramesine
After having analyzed the spheroids exposed to sira-
mesine with PI uptake, the spheroids were fixed in 4%
formalin for 24 h followed by paraffin embedding.
Three-micrometer sections of the paraffin-embedded
spheroids were cut on a microtome. Thereafter one
section was hematoxylin eosin stained and adjacent
sections immunohistochemically stained on a Dako
autostainer, Universal Staining System. For immunohisto-
chemical staining, paraffin sections were deparaffinized
and heat-induced epitope retrieval was performed by incu-
bation in a TEG buffer solution of 10 mmol/L Trisbase
and 0.5 mmol/L EGTA (CD133, nestin, Bmi-1, Sox 2,
Ki67, Lamp-2, cathepsin B) or EDTA buffer (Cathepsin B).
After blocking of endogenous peroxidase activity by in-
cubation in 1.5% hydrogen peroxide (H2O2), the sec-
tions incubated for 60 min with primary antibodies
against CD133 (1 + 40, CD133/1 W6B3C1, Miltenyi
Biotec), Nestin (1 + 3000, 196908, R&D Systems), Bmi-1
(1 + 400, F6, Upstate Biotechnology), Sox 2 (1 + 400,
245610, R&D Systems), Ki67 (1 + 200, MIB-1, Dako),
Lamp-2 (1 + 2000, H4B4, Developmental Studies
Hybridoma Bank), Cathepsin B (1 + 200, polyclonal,
Abgent) and Cathepsin D (1 + 750, EPR3057Y, Epi-
tomics). Detection of immunohistochemical staining
CD133 was detected by CSAII (Catalysed Signal Ampli-
fication II kit, Dako), nestin, Bmi-1 and sox 2 with
Power Vision (Dako) and Ki-67, Lamp-2, cathepsin B
and cathepsin D was performed by use of the detection
system EnVision (Dako). The visualization was per-
formed using diaminobenzidine as chromogen. Finally,
the sections were counterstained with Haematoxylin
and Eosin (H&E) and cover slips were mounted with
Aquatex. Paraffin sections of tissue microarrays with 28
normal tissues and 12 cancers were used as positive
control. Primary antibody omission was used as nega-
tive control.
Spheroid migration assay
Briefly, a reduced growth factor basement membrane
matrix (Geltrex™, Life Technologies™, Denmark) solution
was mixed with neurobasal medium, and added to each
well in a 12-well plate. Subsequently, the supernatant
was aspirated and the spheroids were placed individually
(1 spheroid/well). Afterwards neurobasal medium was
added to each well and cells were allowed to settle and
migrate for 24 h, while being exposed to siramesine in
increasing concentrations. The cells were monitored by
light microscopy and imaging. The outer diameter of the
migrating cells was measured using ImageJ software,
relatively to spheroid diameter measured at day 0. Cell
death in spheroids was visualized using PI (2 μM).
Preparation of organotypic brain slice cultures
Newborn Wistar rat pups (Taconic Europe, Denmark)
used in the present study were treated according to the
procedures at the Biomedical Laboratory, University of
Southern Denmark.
Organotypic corticostriatal slice cultures were pre-
pared as previous described [13, 14]. Seven days
after the start of culturing the brain slice cultures
were exposed to siramesine and cell death was
examined by PI uptake as described earlier by
Nørregaard et al. [14].
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Preparation of co-cultures
GSS culture spheroids were implanted in the area be-
tween cortex and striatum close to corpus callosum. The
medium was changed to serum-free medium before
implanting the spheroids. The spheroids (200–300 μm)
were incubated in DiO solution (1 mM, Molecular
Probes, Invitrogen) for 24 h, before implanting them in
the brain slice cultures. PI (2 μM, Molecular Probes,
Invitrogen) was added to the medium to monitor cell
death in spheroids and brain slices. Before start of ex-
posure (Day 0) confocal z-stacks with 20 μm steps were
recorded after 1 h of incubation. Thereafter the z-stacks
were superimposed into one image representing the
entire spheroid and surrounding brain tissue. This pro-
cedure was repeated at day 3 and day 6, whereafter the
co-cultures were fixed in 4% formalin and paraffin
embedded.
As a control assay to ensure cell death in the spher-
oids, DiO stained spheroids derived from T78 and T86
were placed on the same type of membranes used for
the co-cultures. Cell death was investigated in the
spheroids exposed to 20 μM siramesine with PI uptake
recording confocal z-stacks as for the brain slice cul-
tures. Cell death in the tumor cells was quantified using
Visiomorph software. A classifier identifying PI uptake
as red staining, co-expression of PI and DiO as yellow
staining and DiO as green staining was created. The
data were illustrated as area of cell death (red + yellow
staining) divided by total spheroid area (red + yellow +
green staining).
Immunohistochemical studies of co-cultures
The fixed and paraffin embedded co-cultures were cut
in three μm sections and immunhistochemical stained.
Immunohistochemistry was performed as described
earlier, using the antibodies CD56 (1 + 100, CO4-
NCAM, Neomarkers) and Vimentin (1 + 200, EP20,
Epitomics) to identify human tumor cells in the rat tis-
sue. A panel of the stem cell markers CD133, Nestin
and Podoplanin (1 + 100, D2-40, Dako) as well as the
proliferation marker Ki-67 was furthermore used as de-
scribed above. The staining of the stem cell markers
were assessed in the implanted spheroids by semi-
quantitative scoring (0, 1+, 2+ and 3+). A Ki-67 labeling
index was measured using the software program Tis-
suemorph (Visiopharm, Hørsholm, Denmark).
Glioblastoma tumor xenografts
The experimental procedure was performed as previ-
ously described [12]. Female Balb/c nude (BALBNU-F,
Taconic) mice were anesthetized subcutaneously and
placed in a stereotactic instrument. Through a burr hole
a 2-μL suspension of 300,000 single cells was injected
into the striatum. Mice (n = 42) were implanted with the
standard cell line U87 (n = 22), and the patient-derived
cell line T78 (n = 20).
Siramesine was dissolved in 0.5% methylcellulose 15
(M7140, Sigma-Aldrich, Denmark) in 0.9% NaCl. Sira-
mesine treatment (100 mg/kg) was administered orally
using a stomach tube. Control animals received 0.5%
methylcellulose 15 in 0.9% NaCl. The treatment in-
cluded biweekly treatment, initiated 1 week after tumor
implantation for U87 implanted mice and 2 weeks after
implantation for T78 implanted mice. U87 mice were
euthanized after 1 week of treatment, whereas T78 mice
were euthanized after 6 weeks of treatment.
The mice were euthanized at the same time point.
When symptoms were observed as described below in
the first mice, all mice were sacrificed to be able to com-
pare the volumes among groups. The brains were re-
moved immediately after death and fixed in 4%
formaldehyde for 48 h. Before paraffin embedding the
brains were divided by coronal sections (1 mm). Subse-
quently, brain sections were cut on a microtome (3 μM),
and stained with H&E as well as Vimentin immunohis-
tochemical staining as described previously. The tumor
volume was determined using the digital software Nano-
Zoomer Digital Pathologi, NDP viewer (Hamamatsu).
Ethics
The official Danish ethical review board named the Regional
Scientific Ethical Committee of the Region of Southern
Demark approved the use of human glioma tissue (permis-
sion J. No. S-VF-20040102) in the current study. Written in-
formant consent was obtained from all participants.
The use of animals for organotypic brain slice cultures
was approved by The Animal Experiments Inspectorate
in Denmark (permission J. No. 2008/561-1572). The rats
(newborn wistar rats, Taconic Denmark, n = 60; 4–6 slice
cultures were obtained per rat) were decapitated and the
brains were removed.
The use of animals for glioblastoma mice xenografts
were approved by The Animal Experiments Inspectorate
in Denmark (permission J. Nr. 2013-15-2934-00973).
Mice (Female Balb c nu/nu mice 7–8 weeks, Taconic
Denmark, n = 42) were anesthetized by a subcutaneous
injection with a mixture of hypnorm and dormicum
(0.12 ml/10 g). The mice were euthanized in a carbon
dioxide chamber upon symptoms such as weight loss
(20% loss of body weight) and general poor state includ-
ing lethargy, hunched posture and failure to groom. The
animals were housed according to national guidelines
(National declaration for animal experiments 2013), and
had free access to food and water.
Statistics
Data following a Gaussian distribution was analyzed
using one-way ANOVA with Dunnett’s post test to
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compare treated cultures with control cultures. Non-
parametric data was analyzed using Kruskal-Wallis with
Dunn’s post test to compare the difference in the sum of
ranks between two columns. Statistical significance was
defined as *P < 0.05, **P < 0.01, ***P < 0.001. EC50 values
were estimated by nonlinear regression. The Pearson
correlation was calculated to quantify the association be-
tween the two variables, WST-1 and LDH. Tumor vol-
ume was compared using unpaired t-test. All statistics
were carried out using Graph Pad Prism 5.0 (Graphpad
Software, San Diego California USA).
Results
Siramesine-induced cell death in human glioma cell lines
The human glioma cell lines U87, U251, T98G and
A172 were exposed to siramesine (0–50 μM). Many cells
detached, rounded up and shrinked and some cells ap-
peared with fragmented nuclei resembling apoptotic
bodies suggesting apoptosis-like cell death as shown for
T98G (Fig. 1a, indicated by arrow). The cell proliferation
was significantly reduced after 24 and 48 h when mea-
sured with the WST-1 proliferation assay (Fig. 1b, upper
panel). The EC50 values (Additional file 1: Table S1)
suggested U87 and A172 to be most sensitive towards
siramesine. An increase in LDH release was seen in U87,
T98G and A172 at slightly higher concentrations than
observed in the WST-1 assay (Fig. 1b, lower panel). No
LDH release was measured for the cell line U251. The
pattern of LDH release was the same after 24 and 48 h,
but the effects were more pronounced after 48 h. When
correlating the data from the WST-1 assay and the LDH
assay, correlation coefficients near −1 for U87, T98G
and A172 (Additional file 2: Figure S2) were found, sug-
gesting an almost linear correlation between the two
assays. The LDH assay, however, seemed to be less sensi-
tive than the WST-1 assay.
Cathepsin or caspase dependent cell death
Inhibition of cathepsins and caspases showed different
results for the different glioma cell lines used (Fig. 1c).
For U87, inhibition of cell proliferation and cell death
was obtained by the cathepsin B inhibitor Ca-074-Me in
both the WST-1 and LDH assay, whereas no inhibition
of the caspase inhibitors were observed. Cathepsin and
caspase inhibitors showed no protection against cell
death for U251, neither in the WST-1 assay nor in the
LDH assay. Proliferation and cell death in T98G was
inhibited by both the cathepsin B inhibitor Ca-074-Me
and the caspase-3 and-7 and caspase 3 inhibitors, z-
DEVD-FMK and z-DEVD-CMK, respectively. In the
WST-1 assay the caspase inhibitors inhibited prolifera-
tion at high concentrations only. In the LDH assay the
cathepsin B inhibitor as well as the caspase inhibitors at
both concentrations inhibited cell death. For A172 cell
proliferation measured with WST-1 was unaffected
whereas cell death in the LDH assay was inhibited by
the caspase-3 and −7 inhibitor z-DEVD-FMK and by
20 μM of the caspase 3 inhibitor z-DEVD-CMK. Unex-
pectedly, when measuring the cell proliferation using the
WST-1 assay, the cathepsin inhibitor Ca-074-Me de-
creased cell proliferation significant without addition of
siramesine. Whether this phenomenon was due to an ef-
fect of the inhibitor on the cells or interference with the
assay is not known. However, when using the LDH assay
this was not observed.
Siramesine induced lysosomal changes in pH
The glioma cell lines, U87, U251, T98G and A172,
stained with acridine orange and exposed to siramesine
(5–30 μM) showed a decrease in red staining and an in-
crease in green staining suggesting changes in lysosomal
pH (Fig. 1d–e).
Cell death in GSS cultures
GSS cultures treated with 10 and 15 μM of siramesine
showed disintegration of spheroids, and often cellular
shrinkage (Additional file 3: Figure S3). Using confocal
microscopy a significant PI uptake was observed already
at 5–10 μM siramesine (Fig. 2a–b).
Secondary spheroid formation assay
Formation of secondary spheroids was seen for all GSS
cultures after treating primary spheroids with siramesine
(Fig. 2c). The number of new spheroids formed for T78
and T86 were already significantly lower at 5 μM sirame-
sine, whereas the number of spheroids for T87 was signifi-
cantly lower after treatment with 15 μM siramesine.
Immunohistochemical staining of siramesine exposed
GSS cultures
H&E staining of histological sections of GSS cultures re-
vealed shrinkage of cells and disintegration of the spher-
oids at concentrations of 5–10 μM (Fig. 2d). In general
GSS cultures expressed all chosen stem cell markers but
different levels of expression were found (images only
shown for T78, Fig. 2d). In cultures exposed to sirame-
sine, CD133 expression was preserved for both surviving
T78 and T87 cells, whereas it disappeared for T86 at
15 μM siramesine. In spheroids exposed to 10 and
15 μM siramesine a decrease in Nestin expression was
found for all three spheroid cultures. For T78 and T87, a
decrease in Bmi-1 staining intensity was seen in the
spheroids exposed to especially 15 μM. No Bmi-1 ex-
pression was seen in T86 spheroids. A small decrease in
Sox2 expression was seen for T86 and T87 upon expos-
ure to 15 μM siramesine.
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Fig. 1 (See legend on next page.)
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The proliferation marker Ki-67 was expressed in all
cell lines and expression was preserved in the cells upon
siramesine treatment.
The expression of caspase 3 was found in control cul-
tures in a few cells in T78 spheroids, none in T86 and in
a number of cells in T87 spheroids. Upon siramesine ex-
posure only a few cells were found positive in T78,
whereas an increase in positive cells was found in T86
spheroids already at 5 μM. The expression in siramesine
exposed T87 spheroids resembled the control cultures.
Lamp-2 was expressed in both control and siramesine
exposed spheroids.
Spheroid migration assay
T78 spheroid migration was rapidly influenced by sira-
mesine exposure (Fig. 3a–t). Already 1 day after expos-
ure, spheroids receiving 20 μM of siramesine showed a
significant decrease in migration distance (P < 0.001)
(Fig. 3u). In T86 spheroids, a significant decrease in cell
migration was found for all exposed groups 2 days after
exposure (P < 0.001) (Fig. 3v). Cell death in the sirame-
sine exposed cultures was visualized using PI (Fig. 4).
Control spheroids showed a diffuse PI uptake but no
uptake in the migrating cells was observed throughout
the experiment (Fig. 4b–c, e–f and h–i). Siramesine ap-
peared to induce cell death in the migrating cells
already 6 h after exposure, but also limited cell death in
the central part of the spheroids (Fig. 4k–l). The PI up-
take increased after 24 and 48 h after exposure
(Fig. 4n–o and q–r).
PI uptake in brain slice cultures
Concentrations of siramesine between 5 and 20 μM did
not induce any cell death in the brain tissue (Fig. 5a–b),
but at concentrations of 50 and 100 μM, PI uptake was
significantly increased in both cortex and striatum
(Fig. 5a–b). Concentrations of 100 μM (Fig. 5a–b) in-
duced a high uptake of PI exceeding the uptake in the
positive control cultures treated with the glutamate re-
ceptor agonist NMDA (Fig. 5a–b) suggesting a pro-
nounced cell death in the brain slice cultures.
PI uptake in siramesine treated co-cultures
No PI uptake in the T78 (Fig. 5c) and T86 (Fig. 5d) im-
planted spheroids was observed in the confocal images.
At day 6, however, in the cultures exposed to 50 and 100
of μM siramesine, extensive PI uptake was seen in the
brain slice cultures (Fig. 5c–d only shown for 100 μM
siramesine) but not in the spheroids.
In order to test whether the low PI uptake in im-
planted spheroids where due to limited diffusion of sira-
mesine through the membrane into brain slice cultures,
DiO labelled spheroids were placed directly on the
membrane. A significant PI uptake in the spheroids was
found confirming the diffusion potential of siramesine
across the membrane (Additional file 4: Figure S4).
Marker expression in siramesine exposed co-cultures
Immunohistochemical staining with anti-human CD56
was used to identify the spheroids and the invasive cells
upon implantation of T78 and T86 into the brain slice
cultures (Fig. 6a). No differences in the tumor migration
area or distance were found (Fig. 6b), however, a ten-
dency towards a change in morphology from cells being
elongated to being more rounded cells were seen in
cultures exposed to 100 μM siramesine (Fig. 6a and
Additional file 5: Figure S5 shown for T78). When ex-
posing the co-cultures to 100 μM Siramesine, 5 out of
12 cultures implanted with T78 disintegrated upon par-
affin embedding and for T86 this number was even
higher loosing 10 out of 12 cultures. The surviving cul-
tures were probably less affected by siramesine thus the
pictures shown for 100 μM might not reflect the disin-
tegrated cultures. Confocal images of disintegrated cul-
tures showed a major PI uptake in the brain tissue and
a small increase in cell death in the spheroids.
Glioblastoma xenografts
U87 tumors had a well-defined tumor border and a
non-invasive growth pattern comprising the majority of
one hemisphere (Fig. 7a–b). T78 tumors displayed a
diffuse growth pattern, with marked infiltration into the
surrounding brain tissue including the contralateral
(See figure on previous page.)
Fig. 1 Effect of siramesine in cell lines. The standard human glioma cell lines U87, A172, T98G and U251 were grown as adherent cell cultures
and exposed to siramesine. a Images of the glioma cell line T98G showed cells which rounded up and shrinked upon siramesine exposure
(arrow). b Upon exposure to siramesine (0–50 μM) cell proliferation (WST-1 assay) cell death (LDH assay) was measured. U87 and A172 were more
sensitive towards siramesine compared to U251 and T98G after both 24 and 48 h as seen in both the WST-1 assay (upper panel) and the LDH
assay (lower panel). c Inhibitors of cathepsins (z-FA-FMK and Ca-074-Me) and caspases (z-DEVD-FMK and z-DEVD-CMK) were used to identify mediators
of siramesine-induced cell death. Cell proliferation (WST-1 assay) and cell death (LDH assay) was measured for all four cell lines, suggesting differential
mechanisms in the different cell lines. d-e Lysosomal involvement was investigated with acridine orange which accumulates in acidic cellular
compartments, primarily in lysosomes resulting in red fluorescence. Acridine orange staining in the glioma cell lines appeared as red dot-like
staining corresponding to the presence of intact lysosomes (0 μM siramesine). Confocal imaging identified loss of red fluorescence in the
lysosomes upon siramesine exposure in all of the glioma cell lines after only 1 h of exposure to siramesine (5–30 μM). This suggested that
siramesine exposure lead to compromised/ruptured lysosomal membranes. Scalebar 100 μm (a), Scalebar 50 μm (e). Data are displayed as
mean values ± SEM, and *P < 0.05, **P < 0.01, ***P < 0.001 were assessed by one-way ANOVA. AU, arbitrary units
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Fig. 2 Effect of siramesine on patient-derived spheroid cultures. The glioblastoma stem cell-like containing spheroid (GSS) cultures T78, T86 and
T87 were exposed to siramesine (0–15 μM) for 24 h. a–b The dye propidium iodide (PI) (red fluorescence) enters dead and dying cells and was
used to identify cell death in spheroids. PI uptake in all three GSS cultures was already seen by 5 μM siramesine and was pronounced at 10–15 μM
siramesine. Hoechst 33324 staining (blue fluorescence) was used to stain all cells to be able to calculate a percentage of PI uptake per spheroid.
c Formation of secondary spheroids from siramesine-exposed primary spheroids was reduced for all three GSS cultures already by 5 μM siramesine.
d After siramesine exposure of T78 primary spheroids, the spheroids were fixed and paraffin embedded for histology. H&E staining and
immunohistochemical staining with CD133, Nestin, Bmi-1, Sox 2, Ki-67, LAMP-2 and caspase 3 of 3 μm histological sections were performed. Only
small fragments and single cells were found at concentrations of 10 and 15 μM, suggesting induction of pronounced cell death by siramesine.
However, CD133 was expressed in both control spheroids and in siramesine treated spheroids. Nestin was expressed in control spheroids and
spheroids exposed to 5 μM siramesine whereas some spheroid residues at 10 and 15 μM had lost the nestin expression. Bmi-1 was expressed
in control spheroids and in the siramesine exposed spheroids and the same pattern was seen for Sox2, Ki-67, Caspase 3 and Lamp-2. These
staining thus suggested a potential for recurrence. Scalebar 100 μm (a and d). Data are displayed as mean values ± SEM, and *P < 0.05, **P < 0.01,
***P < 0.001 were assessed by one-way ANOVA
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hemisphere (Fig. 7c–d). Biweekly treatment with sira-
mesine at 100 mg/kg did not reduce tumor volume in
U87 implanted animals (P = 0.78) (Fig. 7b and e) or T78
tumor xenografts (P = 0.62) (Fig. 7d and f ). The mice
showed no detectable side effects during therapy.
Discussion
Siramesine was found to have a pronounced effect on
standard glioma cell lines and on the more immature
cells in the GSS cultures. Cell death in the glioma cell
lines was proposed to be both cathepsin and caspase-
associated, depending on the cell lines used. The sur-
viving cells in GSS cultures preserved expression of
the stem cell markers used, and maintained a high
proliferation. In the flat surface migration assay sira-
mesine was efficient but in the spheroid-brain slice
culture model and xenograft model siramesine was
without effect.
Fig. 3 Flat surface spheroid migration assay. The glioblastoma stem cell-like containing spheroid (GSS) culture T78 and T86 (images not shown)
were allowed to migrate for 1 day before exposure to siramesine (0–20 μM). a, e, i, m, q Control spheroids revealed a pronounced migration.
Siramesine reduced migration in T78 spheroids at all concentrations; b, f, j, n, r 5 μM, c, g, k, o, s 10 μM, and d, h, l, p, t 20 μM. u The spheroid
diameter including all migrating cells was measured at indicated time-points. T78 spheroids exposed to 20 μM siramesine showed a significantly
reduced migration distance already 1 day after exposure (in total 48 h after start of experiment), compared to control spheroids. v The migration
distance was significantly reduced in T86 spheroids 2 days after siramesine exposure (in total 72 h after start of experiment) at all concentrations.
Control cells received culture medium or DMSO (images not shown) both without siramesine. Scalebar 100 μm (a–t). Data are displayed as mean
values ± SEM, and **P < 0.01, ***P < 0.001 were assessed by one-way ANOVA
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Effect of siramesine on adherent glioma cell lines
The results suggest that glioblastoma cell lines are sensi-
tive towards siramesine. Siramesine appeared efficient
on all cell lines using the WST viability assay. Using the
LDH assay, higher concentrations were needed to pro-
duce a similar effect. The pronounced effect of sirame-
sine on glioblastoma cells is in line with results obtained
by tumor cell lines derived from breast, lung, cervix,
prostate and connective tissue [9–11]. By addition of
cathepsin and caspase inhibitors to the glioma cell lines,
siramesine-induced cell death was suggested to be both
cathepsin- and caspase-associated depending on the cell
lines investigated. Different results have also been found
in other cancers regarding the involvement of caspases
in siramesine-induced cell death. It has been found to be
both caspase-independent [9] and clearly caspase-
dependent [17] but also concentration-dependent [18].
These results might suggest that siramesine stimulates
Fig. 4 Propidium iodide uptake in flat surface spheroid migration assay. The glioblastoma stem cell-like containing spheroid (GSS) culture T78
were allowed to migrate for 1 day before exposure to 10 μM siramesine, while being incubated with the dye propidium iodide (PI), which enters
dead and dying cells. a–i In control spheroids, there was a weak central PI uptake but no uptake was observed in the migrating cells. j–l In
siramesine-exposed spheroids, PI uptake suggested siramesine-induced cell death in the central spheroid itself but also in the migrating cells
already 6 h after exposure. m–r After 24 and 48 h of exposure a pronounced PI uptake was found both in the spheroid and in the migrating cells.
Control cells received culture medium or DMSO (images not shown) both without siramesine. Scalebar 100 μm
Jensen et al. BMC Cancer  (2017) 17:178 Page 10 of 16
Fig. 5 (See legend on next page.)
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different cell death pathways in different cell lines and
settings [19]. A more direct lysosomal involvement was
investigated with acridine orange which accumulates in
acidic cellular compartments, primarily in lysosomes.
Only 1 h after siramesine exposure, a decrease in the
staining was seen corresponding to loss of acidity, most
likely explained by a compromised lysosomal membrane.
The same phenomenon has been described breast cancer
[10, 17], which suggested that the changes in pH hap-
pens before membrane permeabilization, leakage of the
cathepsins to the cytosol and eventually cathepsin medi-
ated cell death.
Effect of siramesine on GSS cultures
Siramesine induced disintegration of spheroids and a
correspondingly increased PI uptake. Together with the
H&E staining and immunohistochemistry for the stem
cell markers, the more immature tumor cells clearly ap-
peared to be affected by siramesine.. Comparing cell
death in the adherent cell lines with the GSS cultures,
the adherent cell lines had EC50 values after 24 h be-
tween 12.6 and 19.3 μM measured by WST-1 assay
whereas EC50 for the GSS cultures was between 4.97
and 8.97 μM measured by PI uptake after 24 h. This
suggested that the GSS cultures containing more imma-
ture stem-like cells might be even more sensitive to-
wards siramesine than the adherent glioma cell lines.
The secondary spheroid formation assay revealed a com-
promised potential of the treated cells to form new
spheroids thereby supporting these results. Although the
more immature stem-like cells seemed to be affected,
some Ki-67 positive cells was found in the remaining
spheroids of all three cultures exposed to 10 and 15 μM
siramesine, thereby proposing a potential for recurrence.
Effect of siramesine on migrating tumor cells
The flat surface spheroid migration assay suggested that
siramesine killed migrating glioma cells. PI uptake in mi-
grating tumor cells already detached from the spheroids
was seen and there was a significant decrease in spher-
oid migration distance. Part of this decrease may also be
explained by tumor cell death in the spheroid itself. In
the organotypic 3D migration assay distance of invasion
was not affected by siramesine in any of the cultures.
However, some of the migrating tumor cells appeared to
have lost their membrane protrusions, appearing as
small rounded cells suggesting a stop in migration.
These cells were primarily seen at concentrations of
100 μM siramesine being however toxic to the brain tis-
sue and thus irrelevant in a clinical setting. It could be
speculated if the lack of effect of siramesine on im-
planted invasive spheroids was due to a phenotypic
migration-related shift making the tumor cells sirame-
sine resistant. A phenotypic shift has previously been de-
scribed as part of the so-called go-or-grow hypothesis,
where cells are shifting from a proliferative to an inva-
sive phenotype [20]. When shifting cells to a substrate
supporting migration an overexpression of cell survival
genes such as bcl-2 family members, and downregula-
tion of mediators of the apoptotic pathways such as the
effector caspases was found in migration glioma cells
[21] favouring cell survival. In the same study a reduc-
tion of genes involved in proliferation was found sug-
gesting the invasive cells to be less proliferative, hence
being a difficult target for chemotherapeutic agents.
Siramesine, however, is not believed to target preferen-
tially the proliferative cells, by being both caspase-
independent and insensitive to bcl-2 [9–11]. Thus the
effect of siramesine should not be reduced on this basis.
The lack of effect on implanted invasive spheroids did
not appear to be caused by a compromised delivery of
siramesine across the membrane. Supratherapeutic con-
centrations of siramesine caused significant cell death in
brain slice cultures grown on the membranes and in
spheroids cultured directly on membranes. Whether the
brain tissue limits the concentration of siramesine reach-
ing the tumor cells or whether the phenotype of the in-
vasive cells are responsible for lack of effects remains to
(See figure on previous page.)
Fig. 5 Effects of siramesine in brain slice cultures with spheroids. Spheroids were implanted into organotypic corticostriatal brain slice cultures
and exposed to siramesine. a Initially, organotypic corticostriatal brain slice cultures without spheroids were exposed to siramesine and the
uptake of propidium iodide (PI) was used to visualize potential siramesine-induced death of normal cultured brain tissue. No PI uptake was seen
in control cultures and in cultures exposed to 10 μM siramesine. A pronounced PI uptake was observed with 100 μM siramesine, PI uptake at this
concentration exceeded cell death in the N-Methyl-D-aspartate (NMDA) treated cultures used as positive control. NMDA is an excitatory amino
acid inducing pronounced neuronal cell death in high concentrations. b Densitometric measurements of PI uptake in both cortex and striatum
revealed significant cell death already at day 3 when the brain slice cultures were exposed to both 50 and 100 μM siramesine. Data was normalized
to NMDA-induced cell death at day 3 set to 100%. c–d Both T78 (c) and T86 (d) spheroids were implanted into brain slice cultures. The spheroids were
labelled with DiO (green) before implantation, whereby tumor cell invasion into the brain slices could be monitored by confocal microscopy. Confocal
z-stacks were recorded before (day 0) and 6 days after (day 6) 10 and 100 μM siramesine exposure. Tumor cell invasion was found in controls and at
both siramesine concentrations at day 3 and 6 in cultures implanted with both T78 and T86 spheroids. No cell death as visualized by PI uptake was
present in spheroids and invasive cells (yellow - overlap between DiO (green) and PI (red)). Results were confirmed by histology in Fig. 6. Control
cells received culture medium or DMSO (images not shown) both without siramesine. Scalebar 600 μm (a), Scalebar 100 μm (c–d). Data are
displayed as mean values ± SEM, and **P < 0.01, ***P < 0.001 were assessed by one-way ANOVA
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be determined. Other studies have investigated the effect
of drugs on migrating/invasive cells and suggest – in line
with the present study – that 3D migration inside brain
tissue is a more challenging model when the aim is to
target migrating tumor cells [22, 23]. Being exposed to
the drug simvastatin, glioma spheroids confronted with
fetal rat brain aggregates showed marked migration of
tumor cells into fetal brain tissue, whereas growth and
migration was prevented in flat surface migration assay
[22]. The same phenomenon was described in another
study [23] with a polyamine inhibitor. In line with the
results from the spheroid-brain slice culture model, the
xenograft model with dosages at 100 mg/kg suggested
no anti-tumor effect of siramesine using both the con-
ventional U87 cell line as well a patient-derived glio-
blastoma spheroid culture. We used a drug dosage based
on previous in vivo cancer studies with obtained effect,
but since our animals showed no sign of side effects
higher drug concentrations might be possible [9, 11, 24].
It could be speculated if the blood–brain-barrier (BBB)
Fig. 6 Immunohistochemical detection of tumor cells in the brain slice cultures. After siramesine exposure of organotypic corticostriatal brain slice
cultures being implanted beforehand with spheroids, these co-cultures were fixed, paraffin embedded, sectioned (3 μm) and immunohistochemically
stained with anti-human specific CD56 in order to identify the tumor cells. For comparison these co-cultures were scanned to monitor invasion and
cell death during exposure as illustrated in Fig. 5. a Invasion of CD56 positive human tumor cells from T78 and T86 spheroids into the surrounding
brain tissue was observed in 3 μm histological sections in all cultures and at all concentrations of siramesine. b No difference in spheroid size, invasion
area and distance was found between control cultures and cultures being exposed to different concentrations of siramesine. The “invasion area” was
defined as the area of cells, which had detached from the spheroids and invaded into the brain tissue. The “invasion distance” was defined
as the maximal distance measured to an invasive cell. Control cells received culture medium or DMSO (images not shown) both without
siramesine. Scalebar 100 μm (a). Data are displayed as mean values ± SEM, and **P < 0.01, ***P < 0.001 were assessed by one-way ANOVA
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prevented siramesine to reach the tumor cells. However,
it has previously been shown that siramesine crossed the
BBB in mice using both per oral and subcutaneous ad-
ministration [7]. BBB is associated with impaired deliv-
ery of drugs [25] but it has been suggested to be
heterogeneously disrupted in glioblastomas being how-
ever still intact near the growing edge of the tumor [26].
Earlier initiation of treatment might have been more
efficient in our study. One previous study showed anti-
tumor effect of siramesine in breast xenografts starting
treatment before, simultaneously, or after tumor inocu-
lation [9]. These animals received a daily dosage of sira-
mesine. However, another siramesine study showed
anti-tumor effect in breast xenografts with a biweekly
treatment schedule being similar to our treatment
schedule [11]. Previously a combination treatment with
siramesine and the chemotherapeutic drug vincristine
showed synergistic cytotoxicity but also individual effect
of both drugs in mice breast xenografts [11]. Hence future
studies testing a set of drugs causing lysosomal membrane
permeabilization might identify new promising candidates
to proceed with, both as monotherapy and combined
therapies.
Conclusions
In the present study siramesine killed glioblastoma cells
and spheroids in vitro and additionally reduced spheroid
formation, thereby suggesting a compromising effect on
tumor stemness. The pronounced anti-migratory effect
of siramesine in a flat surface migration model could not
be reproduced in an organotypic spheroid-brain slice
culture model, or in glioblastoma mice xenografts. In
conclusion the in vitro results suggest a potential of
lysosomal destabilizing drugs in killing glioblastoma
cells, but siramesine itself appears to be without effect
using in vivo-like in vitro models as well as orthotopic
in vivo models.
Fig. 7 Glioblastoma xenograft. Tumor xenografts were generated by injecting tumor cells into the brains of nude Balb/c mice. The mice received
0.5% methylcellulose in 0.9% NaCl (control) or siramesine. After the experiment, the mice brains were fixed, paraffin embedded, sectioned (3 μm)
and immunohistochemically stained with anti-human specific CD56 in order to identify the tumor cells. a–b, e The standard U87 cell line formed
fast growing circumscribed tumors. Siramesine treatment was initiated 1 week after tumor implantation and sustained for 1 week but did not
reduce tumor volume (P = 0.78). c–d, f Patient-derived T78 spheroids formed slower growing invasive tumors. Siramesine treatment was initiated
2 weeks after tumor implantation and sustained for a total of 6 weeks but did not reduce tumor volume (P = 0.62). Scalebar 2 mm (a–d). Data are
displayed as mean values ± SEM, statistical significance was assessed students t-test. AU, arbitraty units
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Additional files
Additional file 1: Table S1. EC50 values obtained using WST-1 and
LDH assays. (PDF 26 kb)
Additional file 2: Figure S2. Correlation between WST-1 and LDH data.
U87, T98G and A172 were exposed to siramesine cell proliferation (WST-1
assay) and cell death (LDH assay) was measured. A correlation between
the WST-1and LDH data was found. The Pearson correlation coefficients,
r, were −0.91, −0.97 and −0.79 for U87, T98G and A172, respectively, all
being highly significant (p < 0.001). No correlation was found for U251
since the LDH level was unaffected by siramesine. (TIF 56 kb)
Additional file 3: Figure S3. Patient-derived spheroids exposed to
siramesine. The glioblastoma stem cell-like containing spheroid (GSS)
cultures T78, T86 and T87 were exposed to siramesine (0-15 μM) for
24 h. Light microscopy imaging showed that the spheroids started to
disintegrate already at 5–10 μM. Scalebar 100 μm. (TIF 2610 kb)
Additional file 4: Figure S4. Propidium iodide uptake in patient-derived
spheroids. In order to evaluate the expected diffusion of siramesine through
the membranes used for culturing of spheroid-brain slice co-cultures,
spheroids alone were placed directly upon these membranes and
exposed to medium with 20 μM siramesine. The medium was present
below the membranes similar to the procedure when culturing brain
slice cultures. (A) Propidium iodide (PI) uptake on day 6 was detected
as both red (arrows) and yellow (arrowheads) fluorescence in both T78
and T86 spheroids compared to control cultures. (B) Measuring PI uptake by
using a software classifier identifying red and yellow staining per total area, a
significant PI uptake was clearly seen, especially on day 6. Scalebar 100 μm.
Data are displayed as mean values ± SEM, and **P< 0.01, ***P< 0.001 were
assessed by one-way ANOVA. AU, arbitrary units. (TIF 7565 kb)
Additional file 5: Figure S5. Morphological shape of invasive tumor
cells upon siramesine exposure. After siramesine exposure of spheroid-
brain slice co-cultures, these were fixed, paraffin embedded, sectioned
(3 μm) and immunohistochemically stained with anti-human specific
CD56 in order to identify the tumor cells. The images show high
magnification of 3 μm thick CD56 stained sections of T78 spheroids
implanted into brain slice cultures. (A-B) Control co-cultures were found
to have elongated invasive tumor cells. (C-D) Co-cultures exposed to
100 μM siramesine appeared to be have more rounded invasive cells
with loss of cell protrusions suggesting a moderate effect of siramesine
on invasive tumor cells. Scalebar 100 μm. (TIF 5073 kb)
Abbreviations
BBB: Blood–brain-barrier; DMSO: Dimethylsulfoxid; GSS: Glioblastoma stem
cell-like containing spheroid; H&E: Haematoxylin and Eosin; LDH: Lactate
dehydrogenase; PI: Propidium iodide
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